

Subt. Form PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

Docket Number
47508-556
(HYZ-069CN2)

Application Number
09/896,692

Applicant
Agrawal

Filing Date
June 29, 2001

Group Art Unit
1635

1 OF 2

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
J3	4,806,463	05/1986	Goodchild et al.	435	5	
	5,470,702	01/1993	Hovanessian et al.	435	5	
	5,591,721	10/1994	Agrawal et al.	514	44	
	5,652,355	07/1997	Metelev et al.	536	24.5	
	5,652,356	07/1997	Agrawal	536	24.5	
	6,608,035	08/2003	Agrawal et al.	514	44	
	6,645,943	11/2003	Agrawal et al.	514	44-	

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
J3	WQ96/12497	05/02/96	PCT				
	WO 98/40058	9/17/1998	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

J3	A1	Agrawal, et al. (1992) "GEM"91 - An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDS", <i>Antisense Res. Dev.</i> 2:261-266
	A2	Agrawal et al. (1994) "Potential for HIV-1 Treatment with Antisense Oligonucleotides", <i>J. Biotech. in Healthcare</i> , 1(2):167-182.
	A3	Agrawal, et al. (1995) "Pharmacokinetics of Antisense Oligonucleotides", <i>Clin. Pharmacokinet.</i> 28(1):7-16
	A4	Agrawal (1996) "Preface" in <i>Methods in Molecular Medicine: Antisense Therapeutics</i> (Agrawal, ed.) pp. v-vii
	A5	Agrawal, et al. (1998) "Pharmacokinetics and Bioavailability of Antisense Oligonucleotides Following Oral and Colorectal Administrations in Experimental Animals", in <i>Handbook of Experimental Pharmacology</i> , Vol. 131: <i>Antisense Research and Application</i> , Springer-Verlag, pp. 525-543
	A6	Agrawal (1999) "Importance of Nucleotide Sequence and Chemical Modifications of Antisense Oligonucleotides," <i>Biochemica et Biophysica Acta</i> 1489:53-68
	A7	Beaucage (1993) "Oligodeoxyribonucleotides Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , (Agrawal, ed.) Humana Press, Totowa, NJ, pp.33-61
	A8	Brown (1993) "A Brief History of Oligonucleotide Synthesis" in <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> , pp. 1-17
	A9	Craig et al. (1997) "Patent strategies in the antisense oligonucleotide based therapeutic approach" <i>Exp. Opin. Ther. Patents</i> 7(10):1175-1182
	A10	Database CAS Registry (2003), (Date of entry: 1997), Registry number 193635-63-1
	A11	Froehner (1993) "Oligodeoxynucleotide Synthesis," <i>Methods in Molecular Biology</i> , Vol. 20: <i>Protocols for Oligonucleotides and Analogs</i> (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 63-80
	A12	Furdon (1989) "RNase II cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds," <i>Nucleic Acids Research</i> , Vol. 17:22, pp. 9193-9205
	A13	Galderisi et al. (1999) "Antisense Oligonucleotides as Therapeutic Agents" <i>J. Cell. Physiol.</i> 181:251-257

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

Subt. Form PTO-1449

Docket Number

Application Number

INFORMATION DISCLOSURE
IN AN APPLICATION47508-556
(HYZ-069CN2)

09/896,692

(Use several sheets if necessary)

Applicant
Agrawal

Filing Date

Group Art Unit

June 29, 2001

1635

Sheet

2

OF

2

- 83
- | | |
|-----|---|
| A14 | Lisiewicz et al. (1992) "Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by Antisense Oligonucleotides: An <i>In Vitro</i> Model for Treatment", <i>Proc. Natl. Acad. Sci. USA</i> 89:11209-11213 |
| A15 | Lisiewicz et al. (1993) "Long-Term Treatment of Human Immunodeficiency Virus-Infected Cells with Antisense Oligonucleotide Phosphorothioates", <i>Proc. Natl. Acad. Sci. USA</i> 90:3860-3864 |
| A16 | Lisiewicz et al. (1994) "Antisense Oligodeoxynucleotide Phosphorothioate Complementary to Gag mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Human Peripheral Blood Cells", <i>Proc. Natl. Acad. Sci. USA</i> 91:7942-7946 |
| A17 | Matsukura et al. (1991) "A New Concept in AIDS Treatment: An Antisense Approach and Its Current Status Towards Clinical Application," in <i>Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS</i> (Wickstrom, ed.), Wiley-Liss, Inc., pp. 159-178 |
| A18 | Meteliev et al. (1998) "HPLC of Oligodeoxyribonucleoside Phosphorothioates", Abstract No. 151268f, <i>Chemical Abstracts</i> , 128(13):272 |
| A19 | Meteliev, et al. (1997) "HPLC of Oligodeoxyribonucleoside Phosphorothioates" <i>Russian Journal of Bioorganic Chemistry</i> , 23(9):673-677, Translated from <i>Bioorganicheskaya Khimiya</i> 23(9):742-746 |
| A20 | Milligan, et al. (1993) "Current Concepts in Antisense Drug Design", <i>Journal of Medicinal Chemistry</i> , 36(14):1923-1937 |
| A21 | Milner et al. (1997) "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," <i>Nature Biotech.</i> 15:537-541 |
| A22 | Palu, G., et al. (1999) "In Pursuit of new developments for gene therapy of human diseases," <i>Journal of Biotechnology</i> , 68:1-13 |
| A23 | Tamm, J., et al. (Aug. 2001) "Antisense therapy in oncology: new hope for an old idea?" <i>The Lancet</i> , 358:489-496 |
| A24 | Uhlmann et al. (1990) "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chem. Rev.</i> 90(4):543-584 |
| A25 | Zamecnik (1996) "History of Antisense Oligonucleotides" in <i>Methods in Molecular Medicine: Antisense Therapeutics</i> (Agrawal, ed.) Humana Press, Totowa, NJ, pp. 1-11 |
| A26 | Zhang et al. (1995) "In Vivo Stability, Disposition and Metabolism of a "Hybrid" Oligonucleotide Phosphorothioate in Rats," <i>Biochem. Pharmacol.</i> 50(4): 545-556 |
| A27 | Zhang et al. (1995) Pharmacokinetics of an Anti-Human Immunodeficiency Virus Antisense Oligodeoxynucleotide Phosphorothioate (GEM 91) in HIV-Infected Subjects", <i>Clin. Pharmacol. Ther.</i> 58(1):44-53. |
| A28 | Zhang et al. (1996) "Pharmacokinetics and Tissue Disposition of a Chimeric Oligodeoxynucleoside Phosphorothioate in Rats After Intravenous Administration," <i>Journal of Pharmacology and Experimental Therapeutics</i> 278(2):971-979 |
| A29 | Zhao, et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside", <i>Bioorganic & Medicinal Chemistry Letters</i> , 10:1051-1054 |

EXAMINER

DATE CONSIDERED

83

EXAMINER: initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

RECEIVED
FEB 9 - 2004
TECH CENTER 1600/2900